radiopharmaceuticals

News

Novartis eyes first-line use of Lutathera after trial win

Novartis is preparing to file for approval of its radioligand therapy Lutathera as a first-line treatment for people with rare neuroendocrine tumours after it showed a ben

News

Roche inks pipeline deals with Orionis, PeptiDream

Roche has bolstered its R&D pipeline in oncology and neuroscience with a pair of partnerships with Orionis Biosciences and PeptiDream, parting with upfront cash of $87

News

Lantheus on POINT in radio-oncology with $2bn licensing deal

Lantheus' pipeline-building drive in radiopharma has continued with a $260 million upfront deal to license rights to two oncology candidates from POINT Biopharma.

News

Actinium eyes filing as conditioning drug for AML aces trial

Actinium Pharma is on course to submit its targeted radiotherapy for acute myeloid leukaemia (AML) patients needing a bone mar

Oncology

Are radiopharmaceuticals the next breakthrough in oncology?

Ben Hargreaves examines what advantages radiopharmaceuticals offer in the treatment of cancer and why there has been interest from big pharma in developing these types of therapies.

Events